FI69476C - Foerfarande foer rening av maenniskans leukocyt-interferon - Google Patents
Foerfarande foer rening av maenniskans leukocyt-interferon Download PDFInfo
- Publication number
- FI69476C FI69476C FI793649A FI793649A FI69476C FI 69476 C FI69476 C FI 69476C FI 793649 A FI793649 A FI 793649A FI 793649 A FI793649 A FI 793649A FI 69476 C FI69476 C FI 69476C
- Authority
- FI
- Finland
- Prior art keywords
- interferon
- buffer
- propanol
- fractions
- eluted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (16)
1. Förfarande för rening av människans leukocyt-interferon, kännetecknat därav, att en vattenhaltig lösning av det orena proteinet förs genom en med en buffert balanserad kolonn, som innehäller en genom cyanopropyl-, cyklohexyl-, fenyl-, oktyl-, oktadekyl- eller glycerylgrupper modifierad porös SiC^-matris under HPLC-betingelser, varvid proteinet först adsorberas och sedan elueras med en stigande eller fallande gradient av ett med vatten blandbart lösningsmedel, sä att det slutligen i bestämda fraktioner av eluatet erhälls i renare form.
2. Förfarande enligt patentkravet 1, kännetecknat därav, att det används en med en buffert balanserad kolonn, som innehäller en genom oktyl- eller glycerylgrupper modifierad porös SiC>2~niatris.
3. Förfarande för framställning av människans leukocyt-interferon som homogent protein, kännetecknat därav, att A) en vattenhaltig lösning av leukocyt-interferon i orent tillständ förs under HPLC-betingelser genom en med buffert balanserad kolonn, som innehäller en genom oktylgrupper modifierad Si02-matris, varvid interferonet först adsorberas och sedan elueras med en stigande gradient av ett med vatten blandbart lösningsmedel i en buffert, sä att det i bestämda fraktioner av eluatet erhäll i renare form,‘ B) dessa i steget A) erhällna bestämda fraktionerna förs genom en med en buffert balanserad kolonn, som innehäller en genom glycerylgrupper modifierad Si02~matris, varvid interferonet först adsorberas och sedan elueras med en fallande gradient av ett med vatten blandbart lösningsmedel i en buffert, sä att det i tydliga huvudtoppar i bestämda fraktioner av eluatet erhälls i renare form; C) dessa i steget B) erhällna fraktionerna, vilka motsvarar den tydliga huvudtoppen, under HPLC-betingelser förs genom en med en buffert balanserad kolonn, som innehäller en genom oktylgrupper modifierad Si02~matris, varvid interferonet först adsorberas och sedan elueras med en blandning av ett med vatten blandbart lösningsmedel och en vattenhaltig buffert, sä att det erhälles i en ____ - ττ. 26 69476 enda tydlig topp i bestämda fraktioner av eluatet som homogent protein och evetuellt upprepas steget C) för att nä yttersta ren-het av produkten.
4. Föfarande enligt patentkravet 3, känneteck- n a t därav, att man som ett med vatten blandbart lösningsmedel använder en alkanol.
5. Förfarande enligt patentkravet 5, känneteck-n a t därav, att man som ett med vatten blandbart lösningsmedel använder n-propanol, i steget A) använder en buffert med ett pH av ca 7,5 och i steget B) en buffert med ett pH av ca 4,0.
6. Förfarande enligt patentkravet 5, känneteck-n a t därav, att den i steget A) användna bufferten är 1 M nat-riumacetat/ättiksyra och n-propanol-gradienten stiger frän 0 till 40 % (volym/volym), att den i steget B) användna bufferten är 0,1 M natriumacetat och n-propanol-gradienten faller frän 72,5 till 50 % (volym/volym) och den i steget C) användna bufferten är 1 M pyridin/2 M myrsvraoch en stigande n-propanol-gradient frän 20 till 40 % (volym/volym) installs.
7. Förfarande enligt patentkravet 6, känneteck-n a t därav, att de bestämda, under de tydliga huvudtopparna anordnade fraktionerna hopsamlas, n-propanolen avlägsnas genom extraktion med n-hexan och fore steget C avlägsnas spären av n-he-xan frän den vattenhaltiga fasen.
8. Förfarande enligt nägot av patentkraven 4-7, känne-t e c k n a t därav, att man erhäller interferon-V^.
9. Förfarande enligt nägot av patentkravet 4-7, känne-t e c k n a t därav, att man erhäller interferon^.
10. Förfarande enligt nägot av patentkraven 4-7, känne-t e c k n a t därav, att man erhäller interferon /^ ·
11. Förfarande enligt nägot av patentkraven 4-7, känne-t e c k n a t därav, att man erhäller interferon
12. Förfarande enligt nägot av patentkraven 4-7, känne-t e c k n a t därav, att man erhäller interferon .
13. Förfarande enligt nägot av patentkraven 4-7, kanne-t e c k n a t därav, att man erhäller interferon Ϋ
14. Förfarande enligt nägot av patentkraven 4-7, känne-t e c k n a t därav, att man erhäller interferon
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96325778A | 1978-11-24 | 1978-11-24 | |
US96325778 | 1978-11-24 | ||
US6237479A | 1979-07-31 | 1979-07-31 | |
US6237479 | 1979-07-31 | ||
US7771079A | 1979-09-21 | 1979-09-21 | |
US7771079 | 1979-09-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI793649A FI793649A (fi) | 1980-05-25 |
FI69476B FI69476B (fi) | 1985-10-31 |
FI69476C true FI69476C (fi) | 1986-02-10 |
Family
ID=27370266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI793649A FI69476C (fi) | 1978-11-24 | 1979-11-21 | Foerfarande foer rening av maenniskans leukocyt-interferon |
Country Status (34)
Country | Link |
---|---|
US (1) | US4289690A (sv) |
JP (1) | JPH07224098A (sv) |
KR (1) | KR830002616B1 (sv) |
AR (1) | AR222359A1 (sv) |
AU (2) | AU535936B2 (sv) |
BE (1) | BE880201A (sv) |
CA (1) | CA1129409A (sv) |
CH (3) | CH654843A5 (sv) |
DE (1) | DE2947134A1 (sv) |
DK (1) | DK161048C (sv) |
DO (1) | DOP1979002953A (sv) |
ES (1) | ES8100502A1 (sv) |
FI (1) | FI69476C (sv) |
FR (1) | FR2442054A1 (sv) |
GB (1) | GB2037296B (sv) |
GR (1) | GR72828B (sv) |
HK (1) | HK26684A (sv) |
IE (1) | IE48882B1 (sv) |
IL (1) | IL58759A (sv) |
IN (1) | IN150740B (sv) |
IT (1) | IT1127253B (sv) |
KE (1) | KE3347A (sv) |
LU (2) | LU81918A1 (sv) |
MC (1) | MC1300A1 (sv) |
MY (1) | MY8500222A (sv) |
NL (1) | NL193085C (sv) |
NO (1) | NO151157C (sv) |
NZ (1) | NZ192201A (sv) |
PH (1) | PH20763A (sv) |
PT (1) | PT70495A (sv) |
RO (1) | RO79132B (sv) |
SE (1) | SE454276B (sv) |
SG (1) | SG71183G (sv) |
YU (1) | YU286179A (sv) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI77877C (sv) * | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Förfarande för framställning och rening av human Le-formig interferonp rotein. |
US6410697B1 (en) * | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
US4530901A (en) * | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6835557B1 (en) | 1980-01-08 | 2004-12-28 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides |
KR860001471B1 (ko) | 1980-04-03 | 1986-09-26 | 비오겐 엔. 브이 | 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법 |
CH657141A5 (de) * | 1980-07-01 | 1986-08-15 | Hoffmann La Roche | Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen. |
US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
EP0062971B1 (en) * | 1981-03-27 | 1990-03-07 | Imperial Chemical Industries Plc | Genetically modified microorganisms |
IL65475A0 (en) * | 1981-04-17 | 1982-07-30 | Meloy Lab | Production of immune interferon and its mrna |
US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
US4810645A (en) * | 1981-08-14 | 1989-03-07 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
JPS58501543A (ja) * | 1981-08-14 | 1983-09-16 | エイ/エス アルフレツド ベンツオン | ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良 |
US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
EP0082481B2 (en) * | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
US5098703A (en) * | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
US4973479A (en) * | 1982-01-15 | 1990-11-27 | Cetus Corporation | Interferon-α61 |
US4975276A (en) * | 1982-01-15 | 1990-12-04 | Cetus Corporation | Interferon-alpha 54 |
ZA83768B (en) * | 1982-03-01 | 1983-10-26 | Hoffmann La Roche | Homogeneous human immune interferon and process therefor |
US6432677B1 (en) | 1982-03-08 | 2002-08-13 | Genentech, Inc. | Non-human animal interferons |
US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
US4534906A (en) * | 1982-11-01 | 1985-08-13 | Genentech, Inc. | Removal of impurities from human leukocyte interferon preparations |
US4432895A (en) * | 1982-11-24 | 1984-02-21 | Hoffmann-La Roche Inc. | Monomeric interferons |
US4820515A (en) * | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
JPS59137417A (ja) * | 1983-01-28 | 1984-08-07 | Morinaga Milk Ind Co Ltd | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 |
IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
US4599306A (en) * | 1983-04-15 | 1986-07-08 | Amgen | Monoclonal antibodies which specifically bind to human immune interferon |
US4723000A (en) * | 1983-07-05 | 1988-02-02 | Biospectrum, Inc. | Human interferon gamma and interleukin-2 |
US4710377A (en) * | 1983-08-19 | 1987-12-01 | American Cyanamid Company | Antigens and monoclonal antibodies reactive against sporozoites of Eimeria spp. |
US4675383A (en) * | 1983-11-15 | 1987-06-23 | The Salk Institute For Biological Studies | Purification of T-cell growth factor |
US4568488A (en) * | 1984-01-11 | 1986-02-04 | Lee Huang Sylvia | Reverse immunoaffinity chromatography purification method |
US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
IL71555A (en) * | 1984-04-15 | 1992-06-21 | State Of Israel Israel Inst Fo | Bovine interferon |
US6242567B1 (en) | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
US6133433A (en) * | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
UA29377C2 (uk) * | 1984-09-19 | 2000-11-15 | Новартіс Аг | Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
US5322837A (en) * | 1985-01-11 | 1994-06-21 | Genetics Institute, Inc. | Homogeneous erythropoietin compositions and methods of using same |
US5792450A (en) * | 1985-02-05 | 1998-08-11 | Chiron Corporation | Purified human CSF-1 |
US5532341A (en) * | 1985-03-28 | 1996-07-02 | Sloan-Kettering Institute For Cancer Research | Human pluripotent hematopoietic colony stimulating factor |
IL79176A (en) * | 1985-06-20 | 1992-06-21 | Kirin Amgen Inc | Process for the recovery of erythropoietin from a fluid |
US4667016A (en) * | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
NZ212523A (en) * | 1985-06-24 | 1989-01-06 | Univ Massey | Mobile phase for purification of proteins by high performance liquid chromatography |
GB8522336D0 (en) * | 1985-09-09 | 1985-10-16 | Biogen Nv | Composition for treatment of allergies |
US4677197A (en) * | 1985-10-30 | 1987-06-30 | Cetus Corporation | Purification method for tumor necrosis factor |
US5427780A (en) * | 1985-10-30 | 1995-06-27 | Biogen, Inc. | Composition comprising Mullerian inhibiting substance-like polypeptides |
US4894439A (en) * | 1986-05-22 | 1990-01-16 | Cetus Corporation | N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes |
US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
US5030559A (en) * | 1986-04-01 | 1991-07-09 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification of metastatic human tumors |
US4935372A (en) * | 1986-05-20 | 1990-06-19 | Dana Farber Cancer Institute | Art nucleotide segments, vectors, cell lines methods of preparation and use |
US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
US4894440A (en) * | 1986-09-17 | 1990-01-16 | Massachusetts Institute Of Technology | Method of isolating megakaryocyte stimulatory factor |
IL84170A0 (en) * | 1986-10-17 | 1988-03-31 | Interferon Sciences Inc | Method for detecting interferon |
US4851220A (en) * | 1986-11-26 | 1989-07-25 | Schering Corporation | Stable oleaginous gel |
US4894330A (en) * | 1986-12-23 | 1990-01-16 | Cetus Corporation | Purification of recombinant beta-interferon incorporating RP-HPLC |
US5190751A (en) * | 1987-01-20 | 1993-03-02 | Schering Corporation | Treatment of certain leukemias with a combination of gamma interferon and alpha interferon |
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
US5034513A (en) * | 1987-05-27 | 1991-07-23 | The United States Of America As Represented By The Secretary Of Agriculture | Avian interleukin-2 |
US4871538A (en) * | 1987-07-13 | 1989-10-03 | Schering Corporation | Insoluble copper-alpha interferon complex |
DE3879085T2 (de) * | 1987-10-21 | 1993-06-24 | Akzo Nv | Snrnp-a-antigen und fragmente davon. |
US5559212A (en) * | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
US5179198A (en) * | 1988-07-11 | 1993-01-12 | Hidechika Okada | Glycoprotein and gene coding therefor |
US5256410A (en) * | 1988-12-01 | 1993-10-26 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
US5661126A (en) * | 1989-01-19 | 1997-08-26 | The General Hospital Corporation | Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression |
WO1990009442A1 (en) * | 1989-02-08 | 1990-08-23 | Uab Research Foundation | Antiproliferation factor |
ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US6221675B1 (en) | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US5849881A (en) * | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
US6100054A (en) * | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
IL94183A (en) | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
US5216128A (en) * | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
GB9013016D0 (en) * | 1990-06-11 | 1990-08-01 | Mars Uk Ltd | Compounds |
JP3230091B2 (ja) * | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | ヒト血清アルブミンの着色抑制方法 |
JPH05508847A (ja) * | 1990-07-02 | 1993-12-09 | ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン | 伝達因子および使用方法 |
EP0538300B1 (de) * | 1990-07-10 | 1994-04-13 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | O-glycosyliertes ifn-alpha |
JP3015969B2 (ja) * | 1990-11-30 | 2000-03-06 | ダイナボット株式会社 | 扁平上皮癌関連抗原蛋白質及び該蛋白質をコードするdna |
DE4113949A1 (de) * | 1991-04-29 | 1992-11-05 | Behringwerke Ag | Schizosaccharomyces spezifische polypeptide |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
EP0625991B1 (en) * | 1992-02-10 | 1999-04-28 | Interferon Sciences, Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
US5521287A (en) * | 1992-05-20 | 1996-05-28 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
US5434249A (en) * | 1992-05-27 | 1995-07-18 | Viragen Inc. | Method for modulating specific activity of inteferon alpha |
EP0648128A4 (en) * | 1992-06-24 | 1995-07-26 | Merck & Co Inc | DNA ENCODING THE INTERLEUKIN PRECURSOR 1-g (b) CONVERSION ENZYME. |
US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
JP3352691B2 (ja) * | 1992-11-30 | 2002-12-03 | アメリカ合衆国 | 哺乳動物の筋肉のnad:アルギニンadp−リボシルトランスフェラーゼ |
FR2701263B1 (fr) * | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
US5550114A (en) | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
US5714344A (en) * | 1993-04-07 | 1998-02-03 | Georgetown University | Protease-derivatized CVF |
WO1994023024A1 (en) * | 1993-04-07 | 1994-10-13 | Georgetown University | Dna encoding cobra c3, cvf1, and cvf2 |
US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
DK0722501T3 (da) * | 1993-10-05 | 2000-08-21 | Miller Brewing | Klonet pullulanase |
US6020465A (en) * | 1993-10-22 | 2000-02-01 | University Of Connecticut | Recombinant avian type i interferon |
US5885567A (en) * | 1993-10-22 | 1999-03-23 | University Of Connecticut | Treatment of infection in fowl by oral administration of avian interferon proteins |
US5681931A (en) * | 1995-03-15 | 1997-10-28 | Becton, Dickinson And Company | Human restrictin |
US5883224A (en) * | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
US5922320A (en) | 1996-06-14 | 1999-07-13 | Georgetown University | Recombinant proCVF |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
DK0942740T3 (da) | 1996-12-06 | 2003-12-15 | Amgen Inc | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme |
FR2774988B1 (fr) * | 1998-02-16 | 2000-05-05 | Commissariat Energie Atomique | Procede de purification de la prpres a partir d'un echantillon biologique et ses applications |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6433144B1 (en) * | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
KR20070007086A (ko) * | 2004-02-02 | 2007-01-12 | 암브룩스, 인코포레이티드 | 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도 |
WO2007071768A1 (en) * | 2005-12-23 | 2007-06-28 | Novo Nordisk A/S | Purification of proteins using preparative reverse phase chromatography (rpc) |
EP2132217A2 (en) * | 2007-02-26 | 2009-12-16 | Alltech Associates Inc. | Ultra-fast chromatography |
RU2452491C1 (ru) * | 2010-11-10 | 2012-06-10 | Александр Иванович Сотниченко | Детоксикант пищеварительного тракта позвоночных |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3699222A (en) * | 1958-03-11 | 1972-10-17 | Nat Res Dev | Production of viral interfering substances |
US3144390A (en) * | 1960-06-28 | 1964-08-11 | Nat Res Dev | Process for the purification of interferon |
GB980227A (en) * | 1962-08-16 | 1965-01-13 | Glaxo Lab Ltd | Purification and/or concentration of material containing interferon |
GB1026726A (en) * | 1962-11-23 | 1966-04-20 | Ici Ltd | New assay technique |
GB1055896A (en) * | 1963-12-10 | 1967-01-18 | Glaxo Lab Ltd | Silica adsorbents in interferon purification and/or concentration |
US3256152A (en) * | 1965-06-14 | 1966-06-14 | Merck & Co Inc | Concentration and purification of interferons, viral inhibiting substances (vis), viral inhibiting factors (vif), or viral inhibitory material |
US3548053A (en) * | 1965-09-07 | 1970-12-15 | Horner Frank W Ltd | Interferon production |
DE1617401A1 (de) * | 1966-05-02 | 1972-02-17 | Centre Nat Rech Scient | Verfahren zur Herstellung von Interferon-Praeparaten |
US3652538A (en) * | 1969-08-08 | 1972-03-28 | Pfizer | Formulation process for polynucleotide homopolymers |
DE2041735A1 (de) * | 1970-08-22 | 1972-02-24 | Merck Patent Gmbh | Thio-pyrimidin-derivate |
US3773924A (en) * | 1970-12-24 | 1973-11-20 | M Ho | Interferon production |
BE790953A (fr) * | 1971-11-05 | 1973-05-03 | Beecham Group Ltd | Matiere biologiquement active |
US3800035A (en) * | 1971-12-07 | 1974-03-26 | Smithkline Corp | Production of interferon from human leukocytes in the absence of serum |
US3948886A (en) * | 1972-03-13 | 1976-04-06 | Icn Pharmaceuticals, Inc. | 6-Substituted purine 3',5'-cyclic nucleotides |
US3819482A (en) * | 1972-05-08 | 1974-06-25 | J Semancik | Method of preparing high yields of double-stranded ribonucleic acid |
US3970749A (en) * | 1973-04-03 | 1976-07-20 | Baugh Clarence L | Interferon production |
US4061538A (en) * | 1973-04-04 | 1977-12-06 | Sandoz Ltd. | Enzymatically oxidizing interferon |
FR2244543B1 (sv) * | 1973-07-27 | 1977-07-01 | Inst Nl Sante Rech Medica | |
US3910824A (en) * | 1973-10-18 | 1975-10-07 | Searle & Co | Interferon assay |
US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
NL7404590A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het reactiveren van interferon. |
US3975344A (en) * | 1974-10-02 | 1976-08-17 | G. D. Searle & Co. | Interferon purification |
JPS5322156B2 (sv) * | 1975-01-07 | 1978-07-06 | ||
US4144126A (en) * | 1975-05-21 | 1979-03-13 | Beecham Group Limited | Cell culture method |
US4100150A (en) * | 1975-11-04 | 1978-07-11 | G. D. Searle & Co. | Stabilization of interferon against mechanical stress using thioctic acid |
NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
US4038139A (en) * | 1976-07-16 | 1977-07-26 | G. D. Searle & Co., Limited | Cell culture medium |
FR2389380B1 (sv) * | 1977-05-02 | 1980-02-29 | Anvar | |
JPH031320A (ja) * | 1989-05-29 | 1991-01-08 | Hitachi Maxell Ltd | 磁性紛末とこれを用いた磁気記録媒体 |
-
1978
- 1978-12-15 IN IN1337/CAL/78A patent/IN150740B/en unknown
-
1979
- 1979-10-25 CH CH2099/85A patent/CH654843A5/de not_active IP Right Cessation
- 1979-10-25 CH CH9589/79A patent/CH653347A5/de not_active IP Right Cessation
- 1979-10-25 CH CH732/86A patent/CH658459A5/de not_active IP Right Cessation
- 1979-11-13 DO DO1979002953A patent/DOP1979002953A/es unknown
- 1979-11-21 FI FI793649A patent/FI69476C/fi not_active IP Right Cessation
- 1979-11-21 MC MC791416A patent/MC1300A1/xx unknown
- 1979-11-21 FR FR7928699A patent/FR2442054A1/fr active Granted
- 1979-11-21 IL IL58759A patent/IL58759A/xx unknown
- 1979-11-22 RO RO99322A patent/RO79132B/ro unknown
- 1979-11-22 DE DE19792947134 patent/DE2947134A1/de active Granted
- 1979-11-22 BE BE0/198235A patent/BE880201A/fr not_active IP Right Cessation
- 1979-11-22 LU LU81918A patent/LU81918A1/de unknown
- 1979-11-22 DK DK496779A patent/DK161048C/da not_active IP Right Cessation
- 1979-11-22 GR GR60567A patent/GR72828B/el unknown
- 1979-11-22 YU YU02861/79A patent/YU286179A/xx unknown
- 1979-11-22 NZ NZ192201A patent/NZ192201A/en unknown
- 1979-11-22 NL NL7908516A patent/NL193085C/nl not_active IP Right Cessation
- 1979-11-22 CA CA340,387A patent/CA1129409A/en not_active Expired
- 1979-11-22 AR AR278993A patent/AR222359A1/es active
- 1979-11-23 PH PH23321A patent/PH20763A/en unknown
- 1979-11-23 ES ES486263A patent/ES8100502A1/es not_active Expired
- 1979-11-23 GB GB7940634A patent/GB2037296B/en not_active Expired
- 1979-11-23 KR KR1019790004122A patent/KR830002616B1/ko active
- 1979-11-23 SE SE7909721A patent/SE454276B/sv not_active IP Right Cessation
- 1979-11-23 IE IE2247/79A patent/IE48882B1/en not_active IP Right Cessation
- 1979-11-23 AU AU53136/79A patent/AU535936B2/en not_active Expired
- 1979-11-23 IT IT27524/79A patent/IT1127253B/it active Protection Beyond IP Right Term
- 1979-11-23 PT PT70495A patent/PT70495A/pt unknown
- 1979-11-23 NO NO793819A patent/NO151157C/no unknown
-
1980
- 1980-07-09 US US06/167,165 patent/US4289690A/en not_active Expired - Lifetime
-
1983
- 1983-06-16 AU AU15866/83A patent/AU561672B2/en not_active Expired
- 1983-11-14 SG SG711/83A patent/SG71183G/en unknown
- 1983-11-16 KE KE3347A patent/KE3347A/xx unknown
-
1984
- 1984-03-22 HK HK266/84A patent/HK26684A/xx not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY222/85A patent/MY8500222A/xx unknown
-
1993
- 1993-06-16 LU LU88314C patent/LU88314I2/fr unknown
-
1994
- 1994-12-28 JP JP6328671A patent/JPH07224098A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI69476C (fi) | Foerfarande foer rening av maenniskans leukocyt-interferon | |
US4503035A (en) | Protein purification process and product | |
Friesen et al. | Purification and molecular characterization of human fibroblast interferon | |
US6350589B1 (en) | Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods | |
FI70721B (fi) | Foerfarande foer framstaellning av maenskligt fibroblast-interferon som homigent protein | |
NZ203364A (en) | Method for purifying human immune interferon;homogeneous human immune interferon | |
JPS6338330B2 (sv) | ||
JPS6178799A (ja) | 蛋白質の相互分離方法 | |
Takao et al. | Chemical characterization of recombinant human leukocyte interferon A using fast atom bombardment mass spectrometry. | |
Kniep et al. | Purification of the T lymphocyte growth factor interleukin‐2 from culture media of human peripheral blood leukocytes (buffy coats) | |
US5417970A (en) | Drugs containing a glycosylated interleukin-2 | |
CA1248448A (en) | PURIFICATION OF BIOLOGICALLY ACTIVE HUMAN IMMUNE INTERFERON-.gamma. | |
AU624625B2 (en) | Non-glycosylated, recombinant human il2 in the reduced form, the process for obtaining it and its use as a medicament | |
WO1988004937A1 (en) | Novel polypeptide having gamma-interferon activity | |
AU618382B2 (en) | Human interferon-gamma, process to prepare said human interferon-gamma, and its use | |
Rubinstein et al. | [67] Purification and characterization of human leukocyte interferons by high-performance liquid chromatography | |
KR840001516B1 (ko) | 인체 섬유아세포 인터페론의 제조방법 | |
MXPA06006357A (es) | Proceso para purificar interferon beta. | |
JPH022390A (ja) | 新規なヒト顆粒球マクロファージコロニー刺激因子 | |
JPS6335598A (ja) | T細胞活性化因子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed | ||
MA | Patent expired |
Owner name: F. HOFFMANN-LA ROCHE AG |